Pressure BioSciences, Inc. is focused on solving the problems inherent in biological sample preparation. The Company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, such as approximately 35,000 pounds per square inch (psi) or greater to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources. Its laboratory instrument, the Barocycler, and its consumables product line, which include its Pressure Used to Lyse Samples for Extraction (PULSE) tubes, and other processing tubes, and application specific kits, such as consumable products and reagents, together make up its PCT Sample Preparation System (PCT SPS). The Company is also the distributor for the Constant Systems cell disruption equipment, parts, and consumables.
Industry, Sector and Symbol:
Average Prices:- 50 Day Moving Avg: $0.26
- 200 Day Moving Avg: $0.25
- 52 Week Range: $0.15 - $0.46
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.38
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.02 million
- Price / Sales: 0.12
- Book Value: ($12.70) per share
- Price / Book: -0.02
Profitability:- EBIDTA: ($3,670,000.00)
- Net Margins: -1,014.68%
- Return on Assets: -1,295.65%
Debt:- Debt-to-Equity Ratio: -0.06%
- Current Ratio: 0.13%
- Quick Ratio: 0.06%
Misc:- Average Volume: 78,205 shs.
- Beta: 2.07
- Short Ratio: 0.04
Frequently Asked Questions for Pressure Biosciences (OTCMKTS:PBIO)
What is Pressure Biosciences' stock symbol?
Pressure Biosciences trades on the OTCMKTS under the ticker symbol "PBIO."
How were Pressure Biosciences' earnings last quarter?
Pressure Biosciences Inc (OTCMKTS:PBIO) posted its quarterly earnings data on Tuesday, May, 16th. The company reported ($0.18) earnings per share for the quarter. The firm had revenue of $0.55 million for the quarter. View Pressure Biosciences' Earnings History.
Who are some of Pressure Biosciences' key competitors?
Some companies that are related to Pressure Biosciences include Johnson & Johnson (JNJ), Roche Holding (RHHBY), Pfizer (PFE), Novartis AG (NVS), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), Sanofi (SNY), Amgen (AMGN), Medtronic PLC (MDT), Bayer AG (BAYRY), AbbVie (ABBV), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN) and Gilead Sciences (GILD).
Who are Pressure Biosciences' key executives?
Pressure Biosciences' management team includes the folowing people:
- Jeffery N. Peterson, Independent Chairman of the Board
- Richard T. Schumacher, President, Chief Executive Officer, Treasurer, Secretary, Clerk, Director
- Joseph L. Damasio Jr., Chief Financial Officer, Vice President - Finance
- Edmund Y. Ting Ph.D., Senior Vice President - Engineering
- Nathan P. Lawrence Ph.D., Vice President of Sales and Marketing
- Alexander V. Lazarev Ph.D., Vice President - Research & Development
- Michael S. Urdea, Director
- Vito J. Mangiardi, Independent Director
- Kevin A. Pollack, Independent Director
How do I buy Pressure Biosciences stock?
Shares of Pressure Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pressure Biosciences' stock price today?
One share of Pressure Biosciences stock can currently be purchased for approximately $0.22.
MarketBeat Community Rating for Pressure Biosciences (OTCMKTS PBIO)MarketBeat's community ratings are surveys of what our community members think about Pressure Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Pressure Biosciences (OTCMKTS:PBIO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Pressure Biosciences (OTCMKTS:PBIO)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Pressure Biosciences (OTCMKTS:PBIO)Earnings History by Quarter for Pressure Biosciences (OTCMKTS PBIO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/16/2017 | Q1 2017 | | ($0.18) | | $0.55 million | View | N/A |  |
| 8/17/2015 | | ($0.04) | ($0.09) | $0.58 million | $0.41 million | View | N/A | |
| 4/1/2015 | | ($0.07) | ($0.09) | $0.50 million | $0.29 million | View | N/A | |
| 11/17/2014 | | ($0.11) | ($0.07) | $0.46 million | $0.37 million | View | N/A | |
| 8/14/2014 | | ($0.11) | ($0.05) | $0.39 million | $0.31 million | View | N/A | |
| 5/15/2014 | | ($0.10) | ($0.25) | $0.34 million | $0.40 million | View | N/A | |
| 4/2/2014 | | ($0.07) | ($0.14) | | | View | N/A | |
| 8/15/2013 | Q2 2013 | ($0.06) | ($0.10) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Pressure Biosciences (OTCMKTS:PBIO)Current Year EPS Consensus Estimate: $-0.28 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS
Dividend History for Pressure Biosciences (OTCMKTS:PBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pressure Biosciences (OTCMKTS:PBIO)Insider Ownership Percentage: 20.80%
Insider Trades by Quarter for Pressure Biosciences (OTCMKTS:PBIO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/26/2014 | Richard T Schumacher | CEO | Buy | 13,200 | $0.30 | $3,960.00 | |
| 9/13/2013 | Richard T Schumacher | CEO | Buy | 2,500 | $0.31 | $775.00 | |
| 9/12/2013 | Richard T Schumacher | CEO | Buy | 20,500 | $0.30 | $6,150.00 | |
| 9/9/2013 | Richard T Schumacher | CEO | Buy | 15,500 | $0.28 | $4,340.00 | |
| 8/30/2013 | Michael S Urdea | Director | Buy | 50,000 | $0.29 | $14,500.00 | |
| 8/30/2013 | Richard T Schumacher | CEO | Buy | 10,000 | $0.29 | $2,900.00 | |
| 8/28/2013 | Richard T Schumacher | CEO | Buy | 15,000 | $0.28 | $4,200.00 | |
| 8/23/2013 | Richard T Schumacher | CEO | Buy | 20,000 | $0.27 | $5,400.00 | |
| 8/21/2013 | Kevin Pollack | Director | Buy | 10,000 | $0.28 | $2,800.00 | |
| 10/8/2012 | Clayton A Struve | Major Shareholder | Buy | 76,350 | $0.38 | $29,013.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Pressure Biosciences (OTCMKTS:PBIO)
Latest Headlines for Pressure Biosciences (OTCMKTS:PBIO)
| Source: |
|
| Date | Headline |
|---|
 | Dr. Ruedi Aebersold Receives the Prestigious Karger Medal Recognizing an Individual Who Has Significantly Contributed to the Development of New Bioanalytical Methods
finance.yahoo.com - June 5 at 7:45 PM |
| Pressure BioSciences, Inc. Announces One-for-Thirty Reverse Stock Split
finance.yahoo.com - June 2 at 9:34 PM |
| PBIO: Significant Revenue Growth Expected for 2017 and Beyond
finance.yahoo.com - June 1 at 3:25 PM |
| Pressure BioSciences, Inc. :PBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
finance.yahoo.com - May 26 at 8:20 PM |
 | Pressure Biosciences Inc (PBIO) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 17 at 10:54 AM |
| Pressure BioSciences, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 16 at 6:49 PM |
| Pressure BioSciences, Inc. to Discuss First Quarter 2017 Financial Results and Provide Business Update
finance.yahoo.com - May 15 at 6:24 PM |
| Pressure BioSciences, Inc. Appoints Joseph L. Damasio Jr. as Vice President of Finance and Chief Financial Officer
finance.yahoo.com - April 17 at 9:38 AM |
| WallStreet Research(TM) Announces Availability of Updated Corporate Profile Coverage on Pressure BioSciences, Inc. (OTCQB: PBIO)
finance.yahoo.com - March 29 at 9:13 AM |
| PRESSURE BIOSCIENCES INC Financials
finance.yahoo.com - March 28 at 6:54 PM |
| Pressure BioSciences, Inc. Significantly Expands Marketing and Sales Capabilities
finance.yahoo.com - March 23 at 7:38 PM |
| Pressure BioSciences, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Business Update
finance.yahoo.com - March 22 at 7:07 PM |
| PRESSURE BIOSCIENCES INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 22 at 7:07 PM |
| Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2016 Financial Results and Provide Business Update
finance.yahoo.com - March 21 at 11:07 AM |
 | FinancialBuzz.com Innovation in the Sample Preparation Market
www.bizjournals.com - March 1 at 10:17 AM |
| Pressure BioSciences Receives 2017 North American Excellence Award: "Best New Instrument for Sample Preparation"
finance.yahoo.com - March 1 at 10:17 AM |
| Pressure BioSciences Ramps Up Commercialization of Next-Generation Instrument with CE Marking -- SECFilings.com
finance.yahoo.com - February 9 at 8:38 PM |
| Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
finance.yahoo.com - February 8 at 8:06 PM |
| Pressure BioSciences Achieves CE Marking for its Next Generation Sample Preparation Instrument, the Barocycler 2320EXTREME
finance.yahoo.com - February 2 at 8:02 PM |
| Pressure BioSciences, Inc. to Present at RedChip's Global Online Growth Conference
finance.yahoo.com - January 24 at 7:53 PM |
| Pressure BioSciences, Inc. to Present at the 2017 Biotech Showcase
finance.yahoo.com - January 10 at 7:59 PM |
| PRESSURE BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - January 3 at 11:45 PM |
| Pressure BioSciences, Inc. Well Positioned to Play Important Role in US's $1.8 Billion "Cancer Moonshot" Initiative
finance.yahoo.com - December 16 at 7:53 PM |
| Karyopharm Therapeutics CEO And CFO Talk Company Finances, Partnerships And Pipeline
finance.yahoo.com - December 7 at 7:02 PM |
| Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
finance.yahoo.com - December 5 at 7:04 PM |
| WallStreet Research Announces Availability of Updated Corporate Profile Coverage On Pressure BioSciences, Inc. (OTCQB: PBIO)
finance.yahoo.com - November 21 at 12:01 PM |
| Pressure BioSciences (PBIO) Achieves Record Revenue on Road to Profitability -- SECFilings.com
finance.yahoo.com - November 21 at 12:01 PM |
| PBIO: Update on Third Quarter Financials
finance.yahoo.com - November 21 at 12:01 PM |
| Pressure BioSciences, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update
finance.yahoo.com - November 16 at 7:02 PM |
| Q3 2016 Pressure Biosciences Inc Earnings Release - Time Not Supplied
biz.yahoo.com - November 16 at 10:27 AM |
| 9:19 am Pressure BioSciences announces the initial close of $610K in gross proceeds in a $2.5 mln private placement
finance.yahoo.com - November 14 at 7:01 PM |
| Pressure BioSciences Announces Initial Close of $610,000 in $2.5 Million Private Placement
finance.yahoo.com - November 14 at 10:50 AM |
| Pressure BioSciences, Inc. to Discuss Third Quarter 2016 Financial Results and Provide Business Update
finance.yahoo.com - November 11 at 6:31 PM |
| Pressure BioSciences (PBIO) Secures Funding Allowing for Accelerated Corporate Development -- SECFilings.com
finance.yahoo.com - November 4 at 10:21 AM |
| Pressure BioSciences, Inc. Closes $2,000,000 Line-of-Credit
finance.yahoo.com - November 3 at 10:49 AM |
| How to Invest in the Cancer Moonshot -- SECFilings.com
finance.yahoo.com - October 27 at 11:37 AM |
| Pressure BioSciences' PCT Platform Featured at Official Launch of Major Cancer Research Center Recently Chosen as a Collaborator in the US "Cancer Moonshot" Initiative
finance.yahoo.com - October 26 at 6:45 PM |
| Pressure BioSciences, Inc. to Present at the Fall SeeThruEquity Microcap Investment Conference in New York City
finance.yahoo.com - October 17 at 11:49 AM |
| PBIO: Revenue Continues to Grow Nicely for Second Quarter 2016
finance.yahoo.com - August 17 at 7:02 PM |
| Pressure BioSciences Announces Initial Shipments of its Enabling, Next-Generation PCT System
finance.yahoo.com - July 21 at 10:48 AM |
Pressure Biosciences (PBIO) Chart for Thursday, June, 22, 2017
